Home > Newsletters > FDAnews Device Daily Bulletin > NIR Diagnostics Extends Patent Protection for HemoNIR
FDAnews Device Daily Bulletin
Feb. 3, 2005 | Vol. 2 No. 24
NIR Diagnostics Extends Patent Protection for HemoNIR
NIR Diagnostics, a developer of near-infrared diagnostic instruments, has announced the issuance of a U.S. patent titled, "Sample Tab," a patent under license by the company.
The "Sample Tab" patent provides protection for the patient sample interface of the HemoNIR device. HemoNIR is a portable, reagentless co-oximetry device that uses a droplet of whole blood to monitor nonfunctional hemoglobin. The device will reduce the pain of blood testing and provide immediate and accurate blood-test results for carbon monoxide poisoning and methemoglobinemia caused by smoke inhalation and drug use, respectively.
NIR Diagnostics has also licensed a U.S. patent titled, "Method for Calibrating Spectroscopic Apparatus," related to the HemoNIR device, and has two additional patent applications related to HemoNIR that are currently under review by the patent office.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.